Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis

Interstitial lung disease (ILD) is one of the major causes of morbidity and mortality of patients with rheumatoid arthritis (RA). Accompanying the increased number of reports on the development or exacerbation of ILD in RA patients following therapy with biological disease-modifying antirheumatic dr...

Descripción completa

Detalles Bibliográficos
Autor principal: Mori, Shunsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564070/
https://www.ncbi.nlm.nih.gov/pubmed/26401101
http://dx.doi.org/10.4137/CCRPM.S23288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564070/
https://www.ncbi.nlm.nih.gov/pubmed/26401101
http://dx.doi.org/10.4137/CCRPM.S23288

Ejemplares similares